You are here: Industry Insights > Regeneron

News List

Regeneron’s Eylea wins FDA approval pharmatimes
May 15, 2019
Regeneron has announced that its Eyela (aflibercept) injection has been approved by the US Food and Drug Administration (FDA) to treat all stages of diabetic retinopathy (DR), and thereby reduce the risk of blindness.
EU approval for Regeneron and Sanofi’s rheumatoid arthritis drug europeanpharmaceuticalreview
May 07, 2019
The European Commission (EC) has granted marketing authorisation for Regeneron and Sanofi’s Kevzara (sarilumab) for the treatment of rheumatoid arthritis…
Regeneron and Alnylam partner on eye and CNS disease therapies pharmaceutical-technology
April 23, 2019
Regeneron and Alnylam partner on eye and CNS disease therapies.
Regeneron, Alnylam Ink RNAi Alliance contractpharma
April 09, 2019
To discover, develop and commercialize new RNA interference therapeutics for a broad range of diseases
Inovio Completes Enrollment Ahead of Schedule In Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor en-cphi.cn
April 03, 2019
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma (GBM) has completed its enrollment three months ahead of schedule.
Regeneron/Sanofi wins US approval for expanded use of skin drug expressbpd
March 14, 2019
The US Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA’s eczema drug Dupixent to include patients aged between 12 and 17
Regeneron/Sanofi wins US approval for expanded use of skin drug expressbpd
March 13, 2019
The US Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA’s eczema drug Dupixent to include patients aged between 12 and 17.
Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps pharmaphorum
February 27, 2019
Sanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase 3 results in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Sanofi, Regeneron lose patent dispute with Amgen over cholesterol drug pharmaceutical-technology
February 27, 2019
US District Court for the District of Delaware has upheld Amgen’s patent on cholesterol drug Repatha, rejecting a challenge filed by Sanofi and Regeneron.
Regeneron's Libtayo is chugging along in skin cancer. Next stop? First-line lung fiercepharma
February 24, 2019
Regeneron CEO Len Schleifer has called its brand-new cancer drug Libtayo “the engine that could.” And Wednesday, those wondering, “could what?” got a glimpse at what the PD-1 latecomer has done so far.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page